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This study assesses the controversial role of the mitochondrial permeability transition (MPT) in apoptosis.
In primary rat hepatocytes expressing an IkB superrepressor, tumor necrosis factor alpha (TNFa) induced
apoptosis as shown by nuclear morphology, DNA ladder formation, and caspase 3 activation. Confocal
microscopy showed that TNFa induced onset of the MPT and mitochondrial depolarization beginning 9 h after
TNFa treatment. Initially, depolarization and the MPT occurred in only a subset of mitochondria; however, by
12 h after TNFa treatment, virtually all mitochondria were affected. Cyclosporin A (CsA), an inhibitor of the
MPT, blocked TNFa-mediated apoptosis and cytochrome c release. Caspase 3 activation, cytochrome c release,
and apoptotic nuclear morphological changes were induced after onset of the MPT and were prevented by CsA.
Depolarization and onset of the MPT were blocked in hepatocytes expressing DFADD, a dominant negative
mutant of Fas-associated protein with death domain (FADD), or crmA, a natural serpin inhibitor of caspases.
In contrast, Asp-Glu-Val-Asp-cho, an inhibitor of caspase 3, did not block depolarization or onset of the MPT
induced by TNFa, although it inhibited cell death completely. In conclusion, the MPT is an essential compo-
nent in the signaling pathway for TNFa-induced apoptosis in hepatocytes which is required for both cyto-
chrome c release and cell death and functions downstream of FADD and crmA but upstream of caspase 3.
Apoptosis, or programmed cell death, occurs at all stages of
multicellular life and is required during development, immune
system function, tissue remodeling, and cancer defense. Apo-
ptotic signaling includes three stages: signal induction, propa-
gation via a protease cascade, and execution. The signal induc-
tion stage varies with the stimulus but converges on common
propagation and execution stages. The end result of apoptosis
is degradation of various cellular proteins, such as nuclear
lamins and cytoskeletal components, breakdown of the genomic
DNA into internucleosomal fragments, and morphological
changes, including cellular shrinking and surface blebbing. Ul-
timately, the cell and its contents are broken down to mem-
brane-bound fragments that are phagocytosed by adjacent cells
(26, 54).
Tumor necrosis factor alpha (TNFa) is a pleiotropic cyto-
kine that can signal for proliferation, stress, inflammation, and
cell death (73). TNFa participates in many forms of hepatic
pathology, including ischemia/reperfusion injury, alcoholic and
viral hepatitis, and injury from hepatotoxins (13, 20, 22, 38).
Exogenous TNFa induces fulminant liver failure and hepato-
cyte apoptosis (38). The p55 TNFa receptor (TNFR-1) forms
trimers upon binding to TNFa. The cytoplasmic portion of
TNFR-1 then interacts with the adapter protein TNFR-asso-
ciated death domain protein (TRADD) via a conserved se-
quence known as the death domain (31). TRADD serves as the
branch point for TNFR signaling by binding both TNFR-asso-
ciated factor 2 (Traf2) and Fas-associated protein with death
domain (FADD) (30).
Dominant negative versions of Traf2 block NF-kB activation
(43), although Traf2-deficient mice are only mildly impaired in
activating NF-kB (76), suggesting that NF-kB activation is
signaled through both Traf2-dependent and -independent
pathways, possibly involving other Traf family members or RIP
(68). NF-kB activation is induced by sequential activation of
NIK, which associates with Traf2 (44), and IkB kinase, which
phosphorylates IkBa on serines 32 and 36 (18), targeting IkBa
for ubiquitination and degradation (9). The loss of IkB binding
unmasks the nuclear localization signals on NF-kB, resulting in
nuclear relocalization and activation of NF-kB-dependent
transcription (5). Resistance to apoptosis is conferred by NF-
kB, since inhibition of NF-kB activation renders normally re-
sistant cells sensitive to TNFa- and daunorubicin-mediated
cell death (74). This is consistent with previous observations
that transcriptional inhibitors enhance the apoptotic response
to TNFa (37).
FADD’s death effector domain signals apoptosis by binding
to caspase 8, the likely candidate for the proximal protease in
the caspase cascade (6, 45). Cell death mediated by both TNFa
and Fas (a TNFR family member) is blocked in MCF7 cells by
stable expression of a FADD mutant which lacks the death
effector domain (DFADD) and is thus unable to bind caspase
8 (11). In addition, caspase 8 mutants which are non-FADD-
interacting (due to truncation) or are catalytically inactive also
block Fas- and TNFa-mediated cell death in 293 and HeLa
cells (6), further demonstrating the importance of this protein-
protein interaction in signaling receptor-mediated apoptosis.
Caspases are a family of cysteine proteases that cleave their
substrates after aspartate residues (1, 57). Fas-mediated cell
death requires caspase 1, since cells derived from caspase
1-knockout mice resist Fas-mediated apoptosis (36). crmA is a
serpin family protease inhibitor produced by cowpox virus that
* Corresponding author. Mailing address: 326 Burnett-Womack
C.B. 7080, University of North Carolina at Chapel Hill, Chapel Hill,
NC 27599. Phone: (919) 966-0650. Fax: (919) 966-7468. E-mail: dab
@med.unc.edu.
6353








blocks TNFa- and Fas-mediated apoptosis (53, 67). Caspases 1
and 8 are inhibited most strongly by crmA, whereas execution-
ary caspases, including caspase 3 (CPP32/YAMA/apopain),
are 3 to 4 orders of magnitude less sensitive (79). Activation of
caspase 1-like proteases precedes that of caspase 3-like pro-
teases during Fas-mediated apoptosis (19, 64), suggesting that
caspase 1-like proteases participate in the receptor-mediated
signaling stage, while caspase 3-like proteases are part of the
general propagation and/or execution stages of programmed
cell death.
Substantial evidence implicates mitochondria in apoptotic
signaling. Bcl-2, an antiapoptotic proto-oncogene product, is
localized to the mitochondria (17). A series of studies demon-
strated that the induction of the mitochondrial permeability
transition (MPT) in isolated mitochondria induces apoptotic
changes in isolated nuclei (64, 78). Under these conditions,
mitochondria release a 50-kDa apoptotic protease, known as
apoptosis-inducing factor, which induces the nuclear changes
(65). Other studies showed that cytochrome c release from
mitochondria is a strong proapoptotic signal and precedes the
final execution stage of apoptosis (35, 42, 75).
The MPT represents an abrupt increase of permeability of
the inner mitochondrial membrane to solutes with a molecular
mass of less than 1,500 Da (see reference 80 for a review).
Calcium ions, inorganic phosphate, and oxidant chemicals pro-
mote onset of the MPT, whereas cyclosporin A (CsA), an
immunosuppressive endecapeptide, specifically blocks onset of
the MPT. The rapid increase of permeability associated with
the MPT quickly causes depolarization, uncoupling of oxida-
tive phosphorylation, and large-amplitude mitochondrial swell-
ing. Onset of the MPT is caused by the opening of a very large
conductance channel or pore in the inner mitochondrial mem-
brane. The molecular composition of the permeability transi-
tion pore remains uncertain. The pore may be composed in
part of the adenine nucleotide translocator protein in the inner
membrane, cyclophilin in the matrix, porin in the outer mem-
brane, and possibly other proteins at contact sites between the
inner and outer membranes (80).
Cytochrome c is a 12-kDa protein which functions in the
mitochondrial electron transport chain. At physiological ionic
strength, cytochrome c diffuses in the aqueous phase between
the inner and outer membranes (outer compartment) between
complex III (cytochrome bc1) and complex IV (cytochrome
aa3) (15, 25). After large-amplitude swelling, such as that due
to osmotic shock or the MPT, ruptures in the outer membrane
permit the release of cytochrome c (72). Thus, onset of the
MPT with consequent mitochondrial swelling seems a likely
basis for the appearance of cytochrome c in the cytosol during
apoptosis. However, two recent studies reported release of
cytochrome c during apoptosis that was not accompanied by
mitochondrial depolarization (35, 75). Since mitochondrial de-
polarization invariably follows onset of the MPT, the impor-
tance of the MPT in the propagation stage of apoptotic sig-
naling is called into question.
Confocal microscopy can directly visualize onset of the MPT
in individual mitochondria of living cells (48). Onset of the
MPT is inferred from the redistribution of calcein, a fluoro-
phore of 623 Da, from the cytosol into the mitochondria when
mitochondrial membrane permeability increases. The purpose
of this study was to characterize the role of the MPT during
TNFa-mediated apoptosis using confocal microscopy. The re-
sults show that the MPT is induced during apoptosis. In addi-
tion, CsA blocks the onset of the MPT, cytochrome c release,
and apoptotic cell death, showing that MPT is required for
cytochrome c release and apoptosis. We show further that
the onset of the MPT lies downstream from FADD and
crmA-inhibitable caspases but upstream of Asp-Glu-Val-Asp
(DEVD)-inhibitable caspases.
MATERIALS AND METHODS
Reagents. Reagent-grade chemicals were obtained from Sigma (St. Louis,
Mo.) or Fisher Scientific (Pittsburgh, Pa.) unless otherwise noted. Cell culture
media were from Gibco BRL Life Technologies (Gaithersburg, Md.). Murine
TNFa was from R&D Systems, Inc. (Minneapolis, Minn.), and was used at 30
ng/ml (final concentration). CsA was from Sandoz (Basel, Switzerland). Asp-
Glu-Val-aspartic acid aldehyde (DEVD-cho) was from Bachem (King of Prussia,
Pa.). Tetramethylrhodamine methylester (TMRM) and calcein-AM were ob-
tained from Molecular Probes (Eugene, Oreg.).
Primary hepatocyte cultures and infections. Primary rat hepatocytes were
isolated by collagenase perfusion as described previously (29). Cell viability
routinely exceeded 95%. A total of 4 3 106 cells were plated on 100-mm-
diameter tissue culture plates coated with 5 mg of rat tail collagen in Waymouth’s
medium containing 10% fetal calf serum, 0.1 mM insulin, and 0.1 mM dexameth-
asone. After 2 h, cultures were washed with 13 phosphate-buffered saline and
then changed to hormonally defined media (HDM) containing 1 mg of insulin per
ml, 5 mg of transferrin per ml, 3 mM selenium, and 10 nM free fatty acids in
RPMI basal medium. Cells were infected in HDM with 30 PFU/cell (total of 60
PFU/cell for coinfections) for 2 to 5 h at 37°C and then changed to HDM
containing TNFa or other treatments.
Adenoviruses. The adenovirus type 5 (Ad5) variant Ad5IkB, expressing hem-
agglutinin (HA)-tagged IkBa (S32A, S36A), has been described elsewhere (32).
HA-tagged IkB expression was confirmed with Western blotting using an an-
ti-HA monoclonal antibody (Babco, Berkeley, Calif.). The control virus Ad5Luc
expresses luciferase driven by a cytomegalovirus promoter (kind gift from
Branko Stefanovic). Control adenovirus expression was confirmed by luciferase
assays (data not shown). The DFADD (NFD-4)- and crmA-expressing viral
constructs were prepared by standard molecular biology techniques, using pre-
viously described constructs of AU-1-NFD4 (a truncated form of FADD that
functions as a dominant negative protein, tagged with an AU-1 epitope) (11) and
crmA (67), and the adenoviral transfer vector pACCMV.PLPASR (1), which
drives expression with a cytomegalovirus promoter. Adenoviruses were produced
by homologous recombination of truncated human Ad5 dl309 DNA and transfer
vectors in 293 cells, amplified, and purified as described previously (23). crmA
and AU-1-DFADD expression was verified by Western blotting using anti-crmA
polyclonal antiserum (kind gift from M. Tewari and V. M. Dixit) and anti-AU-1
monoclonal antibody (Babco), respectively. Secondary horseradish peroxidase-
conjugated antibodies were from Santa Cruz Biotechnology (Santa Cruz, Calif.)
and were visualized by enhanced chemiluminescence (Amersham Life Science,
Arlington Heights, Ill.). Mobility shift assays for NF-kB DNA binding activity
were performed as described previously (7), using a consensus NF-kB binding
site probe.
Measurement of apoptosis. For quantitation of cell viability (presented as
average 6 standard error of the mean [SEM]), cells were infected and treated as
described above. After 24 h of TNFa treatment, cells were scored as viable or
apoptotic based on morphological criteria and counted. A minimum of 350 cells
were counted for each condition. For propidium iodide nuclear staining, 106 cells
were plated on 60-mm-diameter tissue culture plates coated with 3 mg of rat tail
collagen and then infected and treated as described above. Cells were fixed in 3:1
methanol-acetic acid, stained with 10 mg of propidium iodide per ml, and viewed
with a Zeiss fluorescence microscope at 4003, using a rhodamine filter set. To
assess DNA ladder formation, 4 3 106 cells were digested overnight at 37°C in
0.5 mg of proteinase K per ml–0.5% sarcosyl in 13 phosphate-buffered saline,
treated with 10 mg of RNase A for 1 h at 37°C, then gently extracted with phenol
and chloroform, and analyzed on 2% agarose gels. Amino-4-trifluoromethyl
coumarin (AFC) release assays for caspase 3 activity were performed with a
FluorAce kit (Bio-Rad Laboratories, Hercules, Calif.) according to the manu-
facturer’s instructions. Briefly, whole-cell lysates were combined with 25 mM
z-DEVD-AFC and incubated for 2 h at room temperature. Change in fluores-
cence (excitation at 370 nm and emission at 490 nm) was monitored at 1-h
intervals, converted to picomoles of AFC released by using a standard curve, and
normalized for protein concentration. Assays were performed in duplicate or
triplicate.
Cytochrome c measurements. Mitochondrial and S-100 fractions were pre-
pared from 8 3 106 Ad5IkB-infected hepatocytes by differential centrifugation in
buffer containing 250 mM sucrose as described previously (75). Protein samples
of 25 mg were loaded on sodium dodecyl sulfate–15% polyacrylamide gels,
subjected to electrophoresis, and then electrophoretically transferred to nitro-
cellulose membranes (Schleicher & Schuell, Keene, N.H.). Western blots were
probed with primary monoclonal anti-cytochrome c antibody (Pharmingen, San
Diego, Calif.) and secondary anti-mouse horseradish peroxidase-conjugated an-
tibody (Santa Cruz Biotechnology) and then developed with enhanced chemilu-
minescence (Amersham Life Science).
Confocal microscopy. Cell loading and confocal microscopy were carried out
essentially as described previously (52). Briefly, 106 hepatocytes plated on col-
lagen-coated 40-mm-diameter glass coverslips were infected with adenoviruses
and treated as described above in HDM supplemented with 50 mM HEPES (pH
7.0) to stabilize pH during the confocal measurements. After 6 h of treatment
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with TNFa, cells were loaded with 500 nM TMRM and 1 mM calcein-AM in
KRH buffer (29). Subsequently, the TNFa-containing HDM was replaced after
supplementation with 100 nM TMRM. Images were collected from 7 to 14 h
following TNFa treatment, by using laser scanning confocal microscopy on cells
maintained at 37°C. TMRM fluorescence was excited at 568 nm and emission
was imaged at .590 nm, by using a long-path emission filter. Calcein fluores-
cence was excited at 488 nm and emission was collected at 515 to 560 nm, by
using a band path emission filter.
RESULTS
Apoptosis model. Hepatocytes resist TNFa-mediated apo-
ptosis unless they are also treated with a protein synthesis
inhibitor such as cycloheximide or actinomycin D (37),
which probably reflects the protective role of proteins whose
expression is stimulated by the transcription factor NF-kB
FIG. 1. The IkB superrepressor sensitizes cells to TNFa-mediated apoptosis. Primary hepatocyte cultures were infected with Ad5IkB and then either not treated
or treated for 24 h with TNFa (30 ng/ml). (A and B) Phase-contrast photomicrographs showing cellular morphology of untreated (A) and TNFa-treated (B) cells were
taken at a magnification of 3100. The inset to panel B shows a Western blot for IkB superrepressor expression in uninfected (U) and Ad5IkB-infected (IkB)
hepatocytes. (C and D) Propidium iodide-stained images of untreated (C) and TNFa-treated (D) cells were captured at a magnification of 3400. Arrows indicate
representative apoptotic nuclei. (E) Primary hepatocyte cultures were uninfected (U), infected with control virus Ad5Luc (Luc), or infected with Ad5IkB (IkB) and
then either not treated (h) or treated for 24 h with 30 ng of TNFa per ml (■). Average percent viability 6 SEM is shown. (F) Ad5IkB-infected hepatocytes were either
untreated (Ø) or treated with 30 ng of TNFa per ml (T) for 24 h. DNA was then extracted and analyzed for apoptotic ladder formation. Lane m, DNA markers.
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(74). To render normally unresponsive hepatocytes sensitive
to TNFa-mediated apoptosis, we blocked NF-kB activation
by using an IkBa (S34A, S36A)-expressing adenovirus
(Ad5IkB) (32). This mutant form of IkBa is not phosphor-
ylated and targeted for degradation and thus prevents
NF-kB activation (53). Expression of the HA-tagged IkB
superrepressor after Ad5IkB infection was confirmed by
Western blotting (Fig. 1B, inset). When primary rat hepa-
tocytes overexpressing the IkB superrepressor were treated
with TNFa, the cells lost viability after 24 h, as shown by
morphological changes including rounding, loss of attach-
ment, and increased refractility in phase-contrast images
(Fig. 1B). Cells expressing the IkB superrepressor but not
treated with TNFa did not lose viability (Fig. 1A). Unin-
fected cells and cells infected with a control adenovirus
(Ad5Luc) were not killed after 24 h of TNFa treatment,
while Ad5IkB-infected hepatocytes treated with TNFa dis-
played striking cell death (Fig. 1E).
Hepatocytes expressing the IkB superrepressor and treated
with TNFa fulfilled morphological and biochemical criteria of
apoptosis. When hepatocytes were fixed and stained with pro-
pidium iodide to visualize nuclear morphology, Ad5IkB-in-
fected hepatocytes treated with TNFa displayed nuclear con-
densation and fragmentation (Fig. 1D). Uninfected cells and
cells infected with control virus Ad5Luc displayed normal nu-
clear morphology after exposure to TNFa (data not shown), as
did untreated Ad5IkB-infected cells (Fig. 1C). Additionally,
we prepared genomic DNA from hepatocytes expressing the
IkB superrepressor. DNA ladders were formed in TNFa-
treated but not untreated cells (Fig. 1F). These results show
that expression of the IkB superrepressor sensitizes primary
hepatocytes to TNFa-mediated apoptosis.
TNFa induces mitochondrial effects during apoptosis. To
directly determine the effect of TNFa on mitochondrial func-
tion and membrane permeability, we loaded cells with cationic
TMRM, a red-fluorescing, membrane potential-indicating flu-
orophore, and calcein, a green-fluorescing fluorophore that
localizes to the cytosol under the loading conditions used (48).
After 7 h of treatment with TNFa, the distributions of TMRM
(Fig. 2A, top) and calcein (Fig. 2A, bottom) remained normal
(for comparison, see reference 39). Each red TMRM-labeled
mitochondrion corresponded to a dark void in the green cal-
cein image, showing that the mitochondria were polarized and
impermeable to low-molecular-weight solutes. After 9 h of
exposure to TNFa, approximately one-third to one-half of the
mitochondria lost TMRM fluorescence, indicating depolariza-
tion (Fig. 2B, top). Simultaneously, these mitochondria filled
with calcein fluorescence, demonstrating permeabilization of
the inner mitochondrial membrane to low-molecular-weight
solutes, corresponding to onset of the MPT (Fig. 2B, bottom).
FIG. 2. TNFa induces MPT and mitochondrial depolarization in Ad5IkB-
infected hepatocytes, while uninfected hepatocytes do not undergo TNFa-me-
diated MPT. Primary hepatocytes were treated with TNFa (30 ng/ml) and then
loaded with red-fluorescing TMRM (top row) to monitor mitochondrial depo-
larization and green-fluorescing calcein (bottom row) to monitor the MPT. Red
fluorescence and green fluorescence were monitored simultaneously in living
cells by confocal microscopy. (A to D) Ad5IkB-infected cells. Images are shown
at 7 (A), 9 (B), 11 (C), and 12 (D) h after TNFa treatment. (E and F) Uninfected
hepatocytes. Images are shown at 7 (E) and 13 (F) h after TNFa treatment.
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After 11 h of TNFa treatment, more than two-thirds of the
mitochondria had undergone these changes (Fig. 2C), and
after 12 h, virtually all mitochondria were affected (Fig. 2D).
Mitochondria in normal hepatocytes (not expressing the IkB
superrepressor) treated with TNFa did not depolarize or un-
dergo MPT, since TMRM and calcein distributions did not
change between 7 h (Fig. 2E) and 13 h (Fig. 2F) of treatment.
Overall, these results show that the MPT and mitochondrial
depolarization occurred in hepatocytes overexpressing the IkB
superrepressor in response to TNFa. These mitochondrial
changes began in a subset of mitochondria between 7 and 9 h
after TNFa treatment and progressed to involve all mitochon-
dria by 13 h of treatment.
Onset of the MPT precedes cytochrome c release, nuclear
condensation and caspase 3 activation. Hepatocytes overex-
pressing the IkB superrepressor were treated with TNFa, and
the time courses for caspase 3 activation, cytochrome c release,
and nuclear condensation were determined. Caspase 3 activa-
tion was assessed by using DEVD-AFC, the preferred tet-
rapeptide substrate for caspase 3, conjugated to the fluoro-
phore AFC. Release of the fluorophore is a measure of
protease activity. Caspase 3 activation showed a small increase
at 11 and 12 h after TNFa treatment, but a substantial increase
did not occur until 14 h, well after onset of the MPT (Fig. 3E).
Apoptotic changes in nuclear morphology were first observed
at 10 h after TNFa treatment and were markedly increased at
12 h of treatment (Fig. 3A to D). Cytochrome c release was
assessed by Western blotting analysis of S-100 fractions from
IkB-expressing hepatocytes. The results show that cytochrome
c release was not observed until 9 h after TNFa treatment (Fig.
3F), after onset of the MPT. These results show that onset of
the MPT occurs prior to downstream apoptotic events, includ-
ing nuclear fragmentation, caspase 3 activation, and cyto-
chrome c release.
CsA blocks MPT and apoptosis. CsA is a well-established
inhibitor of the MPT that functions via a mitochondrial cyclo-
philin which appears to interact directly with and inhibit the
permeability pore (27, 66). This MPT-inhibitory effect of CsA
is distinct from its immunosuppressive function, since the MPT
is not blocked by FK506, which has immunosuppressive effects
similar to those of CsA (24, 28). In addition, the MPT is
inhibited by chemical variants of CsA which are not immuno-
suppressive (47, 61, 70). When hepatocytes overexpressing the
IkB superrepressor were treated with TNFa in the presence of
2 mM CsA, mitochondrial depolarization and onset of the
MPT were blocked (Fig. 4), since TMRM and calcein distri-
butions did not change between 7 h (Fig. 4A) and 13 h (Fig.
4D) of treatment, confirming the MPT-inhibitory effect of
CsA.
To test the ability of CsA to protect against TNFa-mediated
apoptosis, we assessed TNFa-induced cell killing of hepato-
cytes expressing the IkB superrepressor in the presence of 0 to
5 mM CsA. At a concentration of 2 mM or more, CsA pre-
vented cell death (Fig. 5A). This concentration is in keeping
with previously reported values, which range from effective
CsA concentrations of 0.5 to 5 mM for hepatocyte cultures (51,
FIG. 3. The MPT precedes nuclear condensation, caspase 3 activation, and cytochrome c release. (A to D) Time course of nuclear morphology. Ad5IkB-infected
hepatocytes were treated with TNFa (30 ng/ml) and then fixed and stained with propidium iodide at 8 (A), 9 (B), 10 (C), and 12 (D) h after TNFa treatment as for
Fig. 1. Arrows indicate apoptotic nuclei. (E) Ad5IkB-infected hepatocytes were treated with TNFa (30 ng/ml) and then lysed and assayed for caspase 3 at 1-h intervals.
Data are presented as average picomoles of AFC released per microgram of protein per hour 6 SEM. (F) Ad5IkB-infected hepatocytes were treated with TNFa (30
ng/ml); then S-100 fractions were prepared at the indicated time points and analyzed for cytochrome c content by Western blotting.
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52) and 0.1 to 10 mM for purified mitochondria (24, 78). Eth-
anol vehicle delivered at 1:1,000, corresponding to the highest
concentration of CsA used, had no effect on cell viability.
TNFa-mediated cell death became morphologically appar-
ent approximately 16 to 18 h after treatment. Death of all cells
was not observed for approximately 24 h. To determine how
long after TNFa treatment CsA could be protective, an inhib-
itor chase experiment was performed. Hepatocytes expressing
the IkB superrepressor were first treated with TNFa; at 2-h
intervals after TNFa treatment, the cells were exposed to 2 mM
CsA. Viability was then assessed after 24 h of TNFa treatment.
Cell death was prevented when CsA was added up to 8 h
following TNFa but was not blocked when CsA was added 10
or more h after TNFa (Fig. 5B), consistent with time of onset
of the MPT.
The MPT is required for caspase 3 activation and cyto-
chrome c release. Caspase 3 was strongly activated in hepato-
cytes expressing the IkB superrepressor and treated with
TNFa (Fig. 6A) but was not active in untreated, IkB-express-
ing cells (Fig. 6A) or in uninfected or control-infected cells
treated with TNFa (data not shown). CsA at 2 mM blocked
caspase 3 activation (Fig. 6A), showing that the MPT is re-
quired for activation of this downstream protease. Ethanol
vehicle (delivered at 1:2,500) had no effect on caspase 3 activ-
ity.
To assess the relationship between MPT and cytochrome c
release, hepatocytes expressing the IkB superrepressor were
either untreated or treated with TNFa with or without CsA.
Mitochondrial and S-100 fractions were then prepared after
14 h and analyzed for cytochrome c content by Western blot-
ting. TNFa treatment induced cytochrome c release, as shown
by the relative increase in cytochrome c in the S-100 fraction
(Fig. 6B, lane 5; Fig. 3F) and decrease in the mitochondrial
fraction (Fig. 6B, lane 2) compared to untreated cells (lanes 1
and 4). CsA treatment blocked the release of cytochrome c
from the mitochondria to the cytosol (lanes 3 and 6), showing
that the MPT is required for cytochrome c release. Ethanol
vehicle had no effect on cytochrome c localization.
To rule out the possibility that CsA protected cells by re-
versing the effect of the IkB superrepressor, we assessed
NF-kB activity by using an electrophoretic mobility shift assay
with nuclear extracts from uninfected and Ad5IkB-infected
hepatocytes treated with 30 ng of TNFa per ml with or without
FIG. 4. CsA blocks MPT and depolarization induced by TNFa. Ad5IkB-infected hepatocytes were treated with TNFa (30 ng/ml) and CsA (2 mM), labeled with
TMRM (top row) and calcein (bottom row), and analyzed as described for Fig. 2. Images are shown at 7 (A), 9 (B), 11 (C), and 13 (D) h after TNFa-plus-CsA treatment.
FIG. 5. CsA blocks TNFa-mediated hepatocyte cell death. (A) Dose re-
sponse of CsA. Ad5IkB-infected hepatocytes were incubated with TNFa (30
ng/ml) and the indicated amounts of CsA for 24 h, and then cell viability was
assessed. Average percent viability 6 SEM is shown. (B) CsA inhibitor chase
experiment. Ad5IkB-infected hepatocytes were treated with TNFa (30 ng/ml)
and CsA (2 mM) was added 2 to 16 h later. Cell viability was assessed after 24 h
of TNFa treatment. Average percent viability 6 SEM is shown.
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2 mM CsA. TNFa treatment for 30 min induced a fourfold
increase in NF-kB DNA binding activity in uninfected cells
(Fig. 6C, lane 2). Unlabeled oligonucleotide probe at 200-fold
excess competed with the labeled probe, demonstrating bind-
ing specificity (lane 7). Ethanol vehicle delivered at 1:2,500 had
no effect on NF-kB DNA binding activity. CsA partially re-
duced the increased NF-kB DNA binding activity in response
to TNFa in uninfected cells (lane 3), consistent with previous
studies (60). In Ad5IkB-infected cells treated with TNFa,
NF-kB DNA binding activity was completely blocked as ex-
pected (lane 5). CsA did not reverse the complete inhibition of
NF-kB DNA binding by the IkB superrepressor (lane 6), con-
firming that the protection from apoptosis mediated by CsA
did not result from reactivating NF-kB. Instead, CsA protected
from TNFa-induced apoptosis by an independent mechanism,
by blocking the MPT (references 8, 51, 52, 66, 69, and 70 and
Fig. 4).
The MPT is downstream from FADD and crmA, and up-
stream from caspase 3-like proteases. Onset of the MPT pre-
cedes caspase 3 activation and apoptotic nuclear alterations,
suggesting that the MPT is an upstream component in apopto-
tic signaling. To address this issue more directly, we used an
adenovirus expressing a truncated, dominant negative mutant
of FADD (Ad5DFADD) to block propagation of apoptotic
signals from the TNFR-TRADD complex (11). Expression of
DFADD in infected cells was confirmed by Western blotting
(Fig. 7A). Coexpression of the IkB superrepressor and
DFADD in hepatocytes resulted in protection from TNFa-
mediated cell death, as expected from previous studies (11)
(Fig. 7B). Coexpression of DFADD and the IkB superrepres-
sor also prevented caspase 3 activation, nuclear condensation,
and DNA ladder formation in response to TNFa (Fig. 7C and
data not shown). The onset of the MPT and mitochondrial
depolarization were completely blocked in TNFa-treated cells
expressing both the IkB superrepressor and DFADD (Fig. 8A
and B), demonstrating that TNFa-induced onset of the MPT
requires FADD.
To assess the role of proximal caspases in signaling to the
mitochondria, we used an adenovirus expressing crmA
(Ad5crmA), a serpin inhibitor of a subset of caspases, includ-
ing caspases 1 and 8 (53, 79). crmA expression was confirmed
by Western blotting (Fig. 7A). Cells coexpressing the IkB su-
perrepressor and crmA were protected from TNFa-mediated
apoptosis, confirming previous findings (67) (Fig. 7B). crmA
and IkB superrepressor coexpression in hepatocytes treated
with TNFa also inhibited caspase 3 activation, nuclear conden-
sation, and DNA ladder formation (Fig. 7C and data not
shown). crmA and IkB superrepressor coexpression blocked
both onset of the MPT and the mitochondrial depolarization
induced by TNFa (Fig. 8C and D). These results show that the
MPT and depolarization lie downstream of the initial induc-
tion of crmA-inhibitable caspases.
To further investigate the relationship of the MPT to the
apoptotic protease cascade, we treated hepatocytes overex-
pressing the IkB superrepressor with TNFa in the presence of
DEVD-cho, a peptide aldehyde which functions as a compet-
itive inhibitor of caspase 3-subfamily proteases (46). A dose-
response study showed that 10 mM was the minimum effective
concentration of DEVD-cho that blocked TNFa-mediated cell
killing (Fig. 9). In addition, 10 mM DEVD-cho prevented nu-
clear condensation and DNA ladder formation (data not
shown). However, in contrast to the effects of DFADD and
FIG. 6. CsA blocks caspase 3 activation and cytochrome c release and does
not reactivate NF-kB. (A and B) Ad5IkB-infected hepatocytes were either un-
treated (Ø) or treated with TNFa (30 ng/ml) alone (T) or with 2 mM CsA (T1C).
(A) Caspase 3 activity was assessed after 24 h. Results are presented as average
picomoles of AFC released per microgram of protein per hour 6 SEM. (B)
Mitochondrial (Mito; lanes 1 to 3) and S-100 (lanes 4 to 6) fractions were
prepared after 14 h and analyzed for cytochrome c content by Western blotting.
(C) Uninfected (U) and Ad5IkB-infected (IkB) hepatocytes were either un-
treated (Ø) or treated with TNFa (30 ng/ml) alone (T) or with 2 mM CsA (T1C)
for 30 min. Nuclear extracts were then prepared and analyzed for NF-kB DNA
binding activity by using an electrophoretic mobility shift assay. In lane 7, a
competition with 200-fold excess unlabeled probe using extract from uninfected,
TNFa-treated cells is shown.
FIG. 7. DFADD and crmA block TNFa-mediated cell death in Ad5IkB-
infected hepatocytes. (A) Western blots showing FADD and crmA expression in
uninfected (U) and infected cells. (B and C) Primary hepatocytes were infected
with Ad5IkB together with Ad5DFADD or Ad5crmA and then treated with
TNFa (30 ng/ml). (B) Cell viability was assessed after 24 h of treatment. Average
percent viability 6 SEM is shown. (C) Caspase 3 activity was assessed after 24 h.
Results are presented as average picomoles of AFC released per microgram of
protein per hour 6 SEM.
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crmA, DEVD-cho did not prevent mitochondrial depolariza-
tion or onset of the MPT in response to TNFa (Fig. 10). Thus,
the MPT is upstream of caspase 3-like proteases in the apo-
ptotic signaling cascade. These hepatocytes remained viable
for at least 48 h after TNFa treatment, suggesting that depo-
larized, permeable mitochondria may recover and continue to
produce ATP under permissive conditions.
DISCUSSION
The MPT plays a causative role in necrotic hepatocyte death
caused by oxidant stress, various toxicants, and ischemia/reper-
fusion (39). The MPT has also been implicated in the patho-
physiology of Reye’s syndrome (69, 70). Here, we show that
TNFa-mediated apoptosis in hepatocytes expressing a super-
repressor of NF-kB also requires the MPT. Hepatocytes ex-
pressing the IkB superrepressor undergo TNFa-mediated ap-
optosis (Fig. 1). During the progression of apoptotic cell death,
the mitochondria depolarize and undergo MPT over several
hours (Fig. 2). We show that the MPT is required for apopto-
sis, since blocking the MPT with CsA prevents cell death (Fig.
5). The onset of the MPT precedes and is required for caspase
3 activation, cytochrome c release, and nuclear condensation
(Fig. 3 and 6). Further, we ordered the MPT within the sig-
naling pathway for TNFa-induced apoptosis, located down-
stream of FADD and crmA-inhibitable caspases and upstream
of caspase 3-like proteases (Fig. 8 and 10).
Our results showing that CsA prevents both the onset of
MPT and apoptotic cell death in hepatocytes support and
extend the work of Kroemer and coworkers, who showed that
MPT induction in purified mitochondria causes apoptotic
changes in isolated nuclei (64, 78). In these studies, various
MPT inhibitors blocked nuclear apoptosis and inhibited the
mitochondrial release of apoptosis-inducing factor, a proapop-
totic protease (65). Our results are also consistent with previ-
ous studies which showed that CsA prevents apoptosis in T
lymphocytes undergoing thymic selection (62), although the
blocking mechanism of CsA was not determined. Our results
indicate that CsA blocks apoptosis through inhibition of the
MPT.
Mitochondrion-derived cytochrome c is a potent inducer
of apoptotic responses in cell-free systems. Two recent in-
dependent studies reported that release of cytochrome c
occurs without accompanying mitochondrial depolarization
(35, 75), an event which invariably follows onset of the MPT.
These results suggested that cytochrome c release occurs
independently of the MPT. In contrast, our results show that
in primary hepatocytes, onset of the MPT precedes cyto-
chrome c release (Fig. 3). Further, the MPT is required for
cytochrome c release, since CsA blocked cytochrome c ac-
cumulation in the cytosol in response to TNFa (Fig. 6B). It
is a formal possibility that CsA blocks cytochrome c release
and the MPT by two different mechanisms which diverge at
the mitochondrial cyclophilin bound by CsA (14); however,
the relative kinetics of the MPT onset (Fig. 2) and cyto-
FIG. 8. The MPT is downstream from FADD and crmA. Hepatocytes were coinfected with Ad5IkB and either Ad5DFADD (A and B) or Ad5crmA (C and D).
The cells were then treated with TNFa (30 ng/ml), labeled with TMRM (top row) and calcein (bottom row), and analyzed as described for Fig. 2. Images are shown
at 7 h (A and C) and 13 h (B and D) after TNFa treatment.
FIG. 9. DEVD-cho blocks TNFa-mediated cell death in Ad5IkB-infected
hepatocytes. Primary hepatocytes were infected with Ad5IkB and treated with
TNFa (30 ng/ml) and the indicated amounts of DEVD-cho. Viability was as-
sessed after 24 h of treatment. Average percent viability 6 SEM is shown.
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chrome c release (Fig. 3) in conjunction with the results of
the inhibition experiments (Fig. 6) argue for a model of
hepatocyte apoptosis in which the MPT causes cytochrome
c release. Our results show that the MPT progresses grad-
ually during TNFa-mediated apoptosis, beginning in a sub-
set of mitochondria and requiring several hours to affect all
mitochondria (Fig. 2A to D). Thus, for several hours during
the apoptotic response, hepatocytes contain both polarized
and depolarized mitochondria, the latter being the presump-
tive source of released cytochrome c. This is one possible
explanation for the observation that cytochrome c is re-
leased within cells containing polarized mitochondria. An-
other possible explanation is suggested by a recent study
which defined two distinct pathways for Fas-mediated apo-
ptosis in different cells. In one pathway, both caspase 3
activation and caspase 8 activation occur relatively late, and
depend on mitochondrial changes and Bcl-2, while in the
other pathway, caspase 8 is activated earlier, and both
caspases 3 and 8 are activated independently of the mito-
chondria and Bcl-2 (58). The discrepancy regarding the role
and timing of mitochondrial changes in our system and
other systems may reflect a similar duality of signaling path-
ways induced by TNFa, in parallel to Fas.
Our results show that onset of the MPT precedes nuclear
condensation and caspase 3 activation during TNFa-mediated
apoptosis (Fig. 3). In addition, we show that the MPT lies
downstream of FADD and crmA-inhibitable caspases and up-
stream of DEVD-sensitive caspases (Fig. 8 and 10). Taken
together, these data demonstrate that the MPT is a necessary
component of apoptotic signal transduction in primary hepa-
tocytes, functioning as an intermediate in the caspase cascade.
A crmA-sensitive caspase functioning upstream of the mito-
chondria is in agreement with studies showing that crmA
blocks apoptosis induced by TNFR or Fas but does not block
killing induced by the proapoptotic mitochondrial protein bax,
bik, or bak (10, 49). A caspase induced by TNFa and Fas
upstream from mitochondria may also explain why mitochon-
drial bcl-2 does not effectively block Fas-mediated cell death
(33), since bcl-2 can be converted from anti- to proapoptotic
function by caspase-mediated cleavage (10). Our preliminary
data indicate that caspase 8 is activated relatively late after
TNFa treatment, similar to the type 2 cells described by Scaf-
fidi et al. (58), and not until after onset of the MPT (data not
shown). Caspase 1 activity is not induced by TNFa in our
system of primary hepatocyte cultures (data not shown). We
are currently pursuing studies to identify the upstream caspase
or caspases (and their targets) involved in initiating TNFa-
mediated MPT and apoptosis.
Cytochrome c release is required for caspase 3 activation
(41, 81), which is consistent with our results that the MPT lies
upstream from caspase 3 activation and is required for cyto-
chrome c release in hepatocytes. A likely scenario is that onset
of the MPT induces mitochondrial swelling, leading to outer
mitochondrial membrane rupture, resulting in cytochrome c
release. Since bcl-2 inhibits both the MPT and cytochrome c
release (35, 65, 75, 78), this implies that bcl-2 functions pri-
marily by blocking the MPT, as previously suggested (65). This
concept is supported by a recent study showing that bcl-xL, an
antiapoptotic bcl-2 family member, regulates mitochondrial
volume homeostasis, preventing the swelling associated with
the MPT (71). Another study indicates that bcl-2 maintains
mitochondrial polarization by enhancing proton efflux in the
presence of uncouplers (63). Further, prevention of cyto-
chrome c release is not the only protective function for bcl-xL,
since cells which survive cytochrome c microinjection (because
they lack caspase 3) undergo TNFa-mediated apoptosis that is
inhibited by bcl-xL (40, 55).
Treatment of isolated mitochondria with the proapoptotic
protein bax induces cytochrome c release without mitochon-
drial swelling (34), suggesting that the MPT is not a univer-
sal requirement for cytochrome c release. However, another
study showed that CsA blocks bax-mediated apoptosis and
FIG. 10. The MPT is upstream from caspase 3. Ad5IkB-infected hepatocytes were treated with TNFa (30 ng/ml) and DEVD-cho (10 mM), labeled with TMRM
(top row) and calcein (bottom row), and analyzed as described for Fig. 2. Images are shown at 7 (A), 9 (B), 11 (C), and 13 (D) h after TNFa treatment.
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cytochrome c release in Jurkat T cells (50), indicating that
bax induces onset of the MPT, which is required for apo-
ptosis, consistent with our results. The mechanism underly-
ing the function of bax is not clear, although there is evi-
dence that bax possesses ion channel-forming activity which
is inhibited by bcl-2 (2, 59). Such channels would be too
small to directly permit cytochrome c release; however, ion
flux through such channels could induce opening of the
permeability pore, ultimately rupturing the outer mitochon-
drial membrane.
There is a 9-h delay before the TNFa-induced MPT begins,
implying that a checkpoint lies between the TNFR-TRADD-
FADD complex and onset of the MPT. Ceramide production
is induced in response to TNFa in the pathway between up-
stream caspases and the mitochondria, since ceramide accu-
mulation is blocked by crmA but not by bcl-2 (16). However,
bcl-2 and not crmA blocks ceramide-mediated apoptosis, indi-
cating that ceramides function upstream from mitochondria
and the MPT (16). This possibility is further supported by
studies showing that cell-permeable C2-ceramide induces mi-
tochondrial effects in hepatocytes (3) and that TNFa treatment
of hepatocytes results in a threefold increase in mitochondrial
ceramide content (21). Together, these results suggest that the
slow accumulation of mitochondrial ceramides may contribute
to an apoptotic checkpoint between upstream caspases and
onset of the MPT during TNFa-mediated apoptosis.
NF-kB activation blocks MPT induction, since cells not ex-
pressing the IkB superrepressor did not undergo depolariza-
tion or the MPT in response to TNFa (Fig. 2E and F). This
finding indicates that an important protective effect of NF-kB
is prevention of the MPT and suggests that NF-kB interferes
with the activation of upstream caspases through transcription
of a caspase inhibitor similar to crmA. Indeed, NF-kB activates
transcription of the caspase inhibitor c-IAP (inhibitor of apo-
ptosis protein), which suppresses apoptosis (12, 77). However,
IAPs are unlikely to block the onset of the MPT, since they
preferentially bind the distal executionary caspases 3 and 7 and
not the proximal caspases (56). In addition, IAPs protect cells
from bik- and bak-mediated apoptosis, indicating that they
target proteases functioning downstream of the mitochondria
(49). Caspase 3 can cleave IkBa in vitro, resulting in a consti-
tutive NF-kB repressor (4), which suggests that distal caspases
may in turn inhibit NF-kB to promote apoptosis, as well as
potentially feeding back to the mitochondria, further amplify-
ing the MPT. In addition, distal caspases may feed back to
amplify proximal caspases. Identification of the NF-kB-induc-
ible gene products that block the upstream pathway will pro-
vide new insights into the mechanisms by which TNFa induces
either proliferation or apoptosis.
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